Amphastar Pharmaceuticals, Inc.
corporate_fare Company Profile
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for AMPH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for AMPH spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Amphastar 10-Q: Q3 Revenue Up 8% to $207.6M, EPS $0.87, Gross Margin Slips to 48.0%
- Amphastar Q3 Revenue Up 8% to $207.6M; Board Adds $50M to Buyback
- Q3 Revenue Climbs 8% to $207.6M as BAQSIMI and Primatene Hit Records
- Amphastar Q2 Revenue Climbs 5% to $183.9M, GAAP EPS $0.67; BAQSIMI Milestone Triggers $100M Payment
- Amphastar Q2 Revenue Hits $183.9M, BAQSIMI® Milestone Triggers $100M Lilly Payment
Financial Snapshot
Short Interest & Short Volume
11.34 days to coverFINRA reported short interest of 4,261,462 shares in AMPH as of the October 30, 2026 settlement, a 1.7% decrease from the prior period — about 11.3 days to cover at its recent average daily volume. On November 20, 2026, 62.9% of AMPH volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.